Chih-Cheng Chen

Chih-Cheng Chen

Auto-generated profile, based on publicly available information

Chih-Cheng Chen

Department of Internal Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CTChao-Ming Tseng
Chao-Ming Tseng
ILI-Chang Lin
I-Chang Lin
CCChi-Yang Chang
Chi-Yang Chang
HWHsiu-Po Wang
Hsiu-Po Wang
CCChih-Cheng Chen
Chih-Cheng Chen
CTChi‐Ming Tai
Chi‐Ming Tai
The role of computed tomography angiography (CTA) on the management of acute overt obscure gastrointestinal bleeding (OGIB) remains unclear. We designed a study to evaluate the impact of CTA before enteroscopy for acute overt OGIB. All patients undergoing CTA followed by enteroscopy for acute overt OGIB were enrolled in this retrospective study. Clinical characteristics and diagnosis were compared between patients with positive and negative CTA findings. We evaluated the impact of CTA on subsequent enteroscopy. From February 2008 to March 2015, 71 patients including 25 patients with positive CTA findings and 46 patients with negative CTA findings, were enrolled. All 25 patients with positive CTA findings were confirmed to have mid GI lesions, a significantly higher proportion than among patients with negative CTA findings (100% vs. 52.2%, respectively; P <0.001). CTA had a higher diagnostic yield for bleeding from tumor origin than from non-tumor origin (80.0% vs. 23.7%, respectively; P <0.001). The diagnostic yield of CTA and enteroscopy was 35.2% and 73.2%, respectively. The lesions could be identified by the initial route of enteroscopy in more patients with positive CTA findings than in those with negative CTA findings (92.0% vs. 47.8%, respectively; P <0.001). Lesions could be identified in seven of the 25 patients (28.0%) with positive CTA findings by using only push enteroscopy instead of single-balloon enteroscopy (SBE), but all 46 patients with negative CTA findings needed SBE for deep small-bowel examination. CTA is useful in the diagnosis of acute overt OGIB, especially in patients with bleeding from tumors. In addition, it also can show the precise location of bleeding, and guide subsequent enteroscopic management.

9 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCChih-Cheng Chen
Chih-Cheng Chen
YHYao-Chun Hsu
Yao-Chun Hsu
CLChing-Tai Lee
Ching-Tai Lee
CHChia-Chang Hsu
Chia-Chang Hsu
CTChi-Ming Tai
Chi-Ming Tai
CCChi-Yang Chang
Chi-Yang Chang
The prevalence rates of Barrett’s esophagus (BE) in western countries are higher than Asian ones, but little is known about their difference among risk factors of BE. The aim of this study is to investigate the associations of various risk factors including central obesity, body mass index (BMI), metabolic syndrome and H. pylori infection, with BE. A total of 161 subjects with BE were enrolled and compared to age- and gender-matched controls randomly sampled (1:4) from check-up center in same hospital. Central obesity was defined by waist circumference (female>80cm; male>90cm), metabolic syndrome by the modified National Cholesterol Education Program Adult Treatment Panel III criteria in Taiwan. Independent risk factors for BE were identified by multiple logistic regression analyses. The mean age for BE was 53.8±13.7 years and 75.8% was male. H. pylori infection status was detected by the rapid urease test with the prevalence of 28.4% and 44.4% in the BE patients and controls, respectively. The univariate logistic regression analyses showed the risk was associated with higher waist circumference (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.78–3.60), metabolic syndrome (OR, 2.02; 95% CI, 1.38–2.96) and negative H. pylori infection (OR, 0.50; 95% CI, 0.34–0.74). However, multivariate logistic regression analyses revealed that BE associated with higher waist circumference (adjusted OR, 2.79; 95% CI, 1.89–4.12) and negative H. pylori infection (adjusted OR, 0.46; 95% CI, 0.30–0.70). Central obesity is associated with a higher risk of BE whereas H. pylori infection with a lower risk in an ethnic Chinese population.

27 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
CTChi‐Ming Tai
Chi‐Ming Tai
CHChun-Kai Huang
Chun-Kai Huang
YYYung-Chieh Yen
Yung-Chieh Yen
PLPo-Chun Lin
Po-Chun Lin
DWDeng-Wu Wang
Deng-Wu Wang
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
Although hepatitis C virus (HCV) prevails in patients receiving methadone maintenance treatment (MMT), most do not receive anti-HCV therapy. This single-center observational study aimed to achieve HCV micro-elimination at an MMT center during the COVID-19 pandemic using a collaborative referral model, which comprised a referral-for-diagnosis stage (January 2020 to August 2020) and an on-site-diagnosis stage (September 2020 to January 2021). A multidisciplinary team was established and all MMT center patients were enrolled. HCV micro-elimination was defined as >90% of HCV-infected patients diagnosed and >80% of HCV-viremic patients treated. A total of 305 MMT patients, including 275 (90.2%) anti-HCV seropositive patients, were enrolled. Among 189 HCV-infected patients needing referral, the accumulative percentage receiving HCV RNA testing increased from 93 (49.2%) at referral-for-diagnosis stage to 168 (88.9%) at on-site-diagnosis stage. Among 138 HCV-viremic patients, the accumulative percentage receiving direct-acting antiviral (DAA) therapy increased from 77 (55.8%) at referral-for-diagnosis stage to 129 (93.5%) at on-site-diagnosis stage. We achieved an HCV RNA testing rate of 92.4% (254/275), an HCV treatment rate of 95.8% (203/212) and a sustained virological response rate of 94.1% (191/203). The collaborative referral model is highly effective in HCV RNA testing and HCV treatment uptake among MMT patients, achieving HCV micro-elimination.

1 June 2014 in Gastroenterology
Verified
Journal Article
Closed access
CCChih-Cheng Chen
Chih-Cheng Chen
KLKai-Wen Liu
Kai-Wen Liu
CTChi‐Ming Tai
Chi‐Ming Tai

24 March 2023 in Viruses
Verified
Journal Article
Open access
PDF file
CTChi‐Ming Tai
Chi‐Ming Tai
MBMing-Jong Bair
Ming-Jong Bair
TCTzu-Haw Chen
Tzu-Haw Chen
CTCheng-Hao Tseng
Cheng-Hao Tseng
CCChih-Cheng Chen
Chih-Cheng Chen
MING-LUNG YuMING-LUNG Yu
MING-LUNG Yu
Community-based screening for the hepatitis C virus (HCV) decreased during the COVID-19 pandemic. We developed a collaborative referral model between a primary clinic (Liouguei District Public Health Center, LDPHC) and a tertiary referral center to increase HCV screening and treatment uptake in a mountainous region of Taiwan. Once-in-a-lifetime hepatitis B and C screening services established by the Taiwan National Health Insurance were performed at LDPHC. Antibody-to-HCV (anti-HCV)-seropositive patients received scheduled referrals and took a shuttle bus to E-Da hospital for HCV RNA testing on their first visit. Direct-acting antiviral agents (DAAs) were prescribed for HCV-viremic patients on their second visit. From October 2020 to September 2022, of 3835 residents eligible for HCV screening in Liouguei District, 1879 (49%) received anti-HCV testing at LDPHC. The overall HCV screening coverage rate increased from 40% before referral to 69.4% after referral. Of the 79 anti-HCV-seropositive patients, 70 (88.6%) were successfully referred. Of the 38 HCV-viremic patients, 35 (92.1%) received DAA therapy, and 32 (91.4%) achieved sustained virological response. The collaborative referral model demonstrates a good model for HCV screening and access to care and treatment in a Taiwan mountainous region, even during the COVID-19 pandemic. Sustained referral is possible using this routine referral model.

21 May 2026 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
TFTsai kun Feng
Tsai kun Feng
CSChia-Tung Shun
Chia-Tung Shun
YFYu-Jen Fang
Yu-Jen Fang
YLYi-Chia Lee
Yi-Chia Lee
THTzu-Chan Hong
Tzu-Chan Hong
JLJyh-Ming Liou
Jyh-Ming Liou
At present, the relevance of insulin-like growth factors in the progression of gastric cancer (GC) remains elusive. We conducted a cohort study to assess the influence of the IGF proteins on GC. We investigated the serum and tissue expression of IGF proteins in patients with GC to determine their biomarker potential. In Cohort 1, the serum levels of IGF1,2, and IGFBP1-3 were measured for survival analysis (N = 142). IGF1,2, IGF-IR,IIR, and IGFBP1-3 in cancer tissues was assessed via immunohistochemistry (N = 28). In Cohort 2 (N = 255), serum IGFBP2 was measured 115 patients diagnosed with gastritis as a control group. In prognostic Cohort 3 (N = 397), IGFBP2 expression was quantitatively assessed in GC tissues. Higher serum IGFBP2 in Cohorts 1 and 2 was associated with worse overall survival (Cohort 1, p < 0.0001; Cohort 2, p < 0.00001). In Cohort 1, IGFBP2 exhibited the highest success staining rate among IGF proteins in GC tissue (92.8%, 26/28; p = 0.006). Cox regression analysis confirmed that higher serum IGFBP2 predicted a worse prognosis (HR: 1.90; p = 0.0011). The serum IGFBP2 levels in GC patients were higher than in the gastritis group (p = 0.0001). Cox regression analysis in Cohort 3 suggested that score 2 and score 1 IGFBP2 expression were independent predictors of poor prognosis (HR: 1.74 for Score 2, p = 0.0079; HR: 1.49 for Score 1, p = 0.039). IGFBP2, but not other IGF proteins, are associated with GC prognosis.